RFK Jr.’s Autism Plan—A Privacy Nightmare?

Colorful blocks spelling 'AUTISM' surrounded by puzzle pieces on a pink background

Washington’s autism policy is shifting fast—and families could gain better medical care while simultaneously losing control over sensitive health data.

Story Snapshot

RFK Jr.’s remade Interagency Autism Coordinating Committee (IACC) released early proposals to change how autism is diagnosed and treated, with a sharper focus on overlooked medical problems.
The recommendations push doctors and Medicaid rules to take seizures, sleep disorders, GI problems, regression, and allergic disease more seriously instead of dismissing symptoms as “just autism.”
The committee also advanced a “profound autism” designation based on support needs, a move that could reshape funding and services.
Federal agency representatives reportedly abstained on key votes, leaving implementation and accountability questions unresolved.
Separate HHS actions—like hiring a controversial researcher and announcing a national autism registry—are fueling ethical and privacy concerns.

What the committee proposed—and why it matters to families

Health and Human Services Secretary Robert F. Kennedy Jr.’s newly reconstituted IACC published four initial proposals on April 28, 2026, ahead of its first meeting in roughly 19 months. The central theme is practical: many autistic people, especially those with higher support needs, have serious co-occurring medical conditions that can be missed or minimized. The proposals argue caregivers’ observations should be treated as medically relevant, not brushed aside during clinical visits.

The committee’s recommendations also point to specific federal levers. One proposal calls for clinician training developed through the Health Resources and Services Administration (HRSA), aiming to standardize how providers recognize and manage medical comorbidities in autistic patients. Another urges Centers for Medicare and Medicaid Services (CMS) guidance to prevent coverage and clinical decision-making from defaulting to “diagnostic overshadowing,” where a documented autism diagnosis becomes a reason to ignore seizures, sleep disruption, gastrointestinal pain, regression, or allergic disease.

“Profound autism” becomes a policy tool, not just a clinical label

During the April 28–29 Washington meeting, the committee voted to recommend a “profound autism” designation, with discussion centered on defining it primarily by support needs and functional limitations. Coverage indicates the approach differs from prior frameworks that leaned more heavily on IQ-based thresholds and from criteria discussed in major medical literature in recent years. That distinction matters because federal definitions often drive downstream decisions on eligibility, program design, and how research and services are prioritized.

Supporters frame the shift as a way to keep high-needs cases from getting lost in broad, one-size-fits-all autism policy. Critics worry new labels can inadvertently stigmatize families or oversimplify a complex spectrum. So far the committee appears to be moving away from the IACC’s previous emphasis areas—genetics, adult employment, and longer-running research priorities—toward immediate safety and medical management topics like wandering risk and preventable health crises.

Who’s on the committee—and why the process is under scrutiny

The politics surrounding the IACC are now inseparable from its policy work. In January 2026, Kennedy removed existing members and appointed 21 new ones, with reports noting the inclusion of vaccine skeptics and more activist-oriented voices. It also indicates federal members abstained on certain proposal votes, which can signal internal caution even when an advisory group’s momentum is moving quickly. The result is a familiar Washington pattern: big policy signaling up front, but uncertain follow-through.

The registry and research agenda raise privacy and trust questions

Separate from the committee’s medical-care proposals, HHS has also announced a national autism registry using insurance, medical, and genetic data, and hired David Geier to study autism-vaccine links—moves that have prompted ethical criticism. Even Americans who agree that autism care needs improvement can reasonably worry about consent, data security, and whether the federal bureaucracy can safeguard intimate health information. When government expands data collection, public trust depends on transparency, narrow purpose limits, and enforceable oversight.

RFK Jr.'s New Autism Committee Issues First Proposals https://t.co/WEeGSKNHQL

— zerohedge (@zerohedge) April 29, 2026

The immediate, least-controversial test will be whether the IACC’s practical recommendations actually translate into better frontline care—more screening for seizures, better sleep and GI evaluation, and clearer Medicaid rules that don’t penalize families for having an autism diagnosis in the chart. The higher-stakes question is whether Washington can pursue better outcomes without drifting into politicized science fights or building new databases that outlive their stated purpose. For families, results—and safeguards—will matter more than rhetoric.